This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus

NCT00531063 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

237

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Transplantation

Interventions

DRUG: Everolimus (RAD001)

Sponsor

Novartis Pharmaceuticals